Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Julia W. Gargano(Canadian Institutes of Health Research), Sara E. Oliver(Centers for Disease Control and Prevention), John R. Su(National Center for Emerging and Zoonotic Infectious Diseases), Danielle Moulia(Centers for Disease Control and Prevention), Stephen C. Hadler(The Task Force for Global Health), Lauri E. Markowitz(Centers for Disease Control and Prevention), José R. Romero(Boston University), Tom T. Shimabukuro(Centers for Disease Control and Prevention), Karen R. Broder(Centers for Disease Control and Prevention), Grace M. Lee, Matthew E. Oster(Children's Healthcare of Atlanta), Heather M. Scobie, H. Keipp Talbot(Marshfield Clinic), Eric Weintraub, Melinda Wharton(Centers for Disease Control and Prevention), Veronica V. McNally, Gayle Langley, Megan Wallace(Centers for Disease Control and Prevention), Julianne Gee, Matthew F. Daley(Kaiser Permanente)
Cited by 602
Related Papers
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
|PsycEXTRA Dataset|2007|1.9k
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k